These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34624191)

  • 1. Indirubin Derivatives as Dual Inhibitors Targeting Cyclin-Dependent Kinase and Histone Deacetylase for Treating Cancer.
    Cao Z; Yang F; Wang J; Gu Z; Lin S; Wang P; An J; Liu T; Li Y; Li Y; Lin H; Zhao Y; He B
    J Med Chem; 2021 Oct; 64(20):15280-15296. PubMed ID: 34624191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
    Cheng C; Yun F; Ullah S; Yuan Q
    Eur J Med Chem; 2020 Mar; 189():112073. PubMed ID: 31991336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
    Duan YC; Jin LF; Ren HM; Zhang SJ; Liu YJ; Xu YT; He ZH; Song Y; Yuan H; Chen SH; Guan YY
    Eur J Med Chem; 2021 Aug; 220():113453. PubMed ID: 33957387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
    Ojha R; Huang HL; HuangFu WC; Wu YW; Nepali K; Lai MJ; Su CJ; Sung TY; Chen YL; Pan SL; Liou JP
    Eur J Med Chem; 2018 Apr; 150():667-677. PubMed ID: 29567459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, in vitro anticancer activity and in silico studies of certain pyrazole-based derivatives as potential inhibitors of cyclin dependent kinases (CDKs).
    Mohammed EZ; Mahmoud WR; George RF; Hassan GS; Omar FA; Georgey HH
    Bioorg Chem; 2021 Nov; 116():105347. PubMed ID: 34555628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
    Wang B; Chen X; Gao J; Su L; Zhang L; Xu H; Luan Y
    Bioorg Med Chem Lett; 2019 Sep; 29(18):2638-2645. PubMed ID: 31400938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and evaluation of novel indirubin-based N-hydroxybenzamides, N-hydroxypropenamides and N-hydroxyheptanamides as histone deacetylase inhibitors and antitumor agents.
    Anh DT; Hai PT; Dung DTM; Dung PTP; Huong LT; Park EJ; Jun HW; Kang JS; Kwon JH; Tung TT; Han SB; Nam NH
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127537. PubMed ID: 32916298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression.
    Mehndiratta S; Lin MH; Wu YW; Chen CH; Wu TY; Chuang KH; Chao MW; Chen YY; Pan SL; Chen MC; Liou JP
    Eur J Med Chem; 2020 Jan; 185():111725. PubMed ID: 31655430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, Synthesis, and Biological Evaluation of 2-Anilino-4-Triazolpyrimidine Derivatives as CDK4/HDACs Inhibitors.
    Wang S; Han S; Cheng W; Miao R; Li S; Tian X; Kan Q
    Drug Des Devel Ther; 2022; 16():1083-1097. PubMed ID: 35431540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and Biological Evaluation of 1-(2-Aminophenyl)-3-arylurea Derivatives as Potential EphA2 and HDAC Dual Inhibitors.
    Zhu Y; Ran T; Chen X; Niu J; Zhao S; Lu T; Tang W
    Chem Pharm Bull (Tokyo); 2016; 64(8):1136-41. PubMed ID: 27477652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and antitumor activity evaluation of novel HDAC inhibitors with tetrahydrobenzothiazole as the skeleton.
    Sun S; Zhao W; Li Y; Chi Z; Fang X; Wang Q; Han Z; Luan Y
    Bioorg Chem; 2021 Mar; 108():104652. PubMed ID: 33497873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
    Cheng C; Yun F; He J; Ullah S; Yuan Q
    Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors.
    Zhu G; Conner SE; Zhou X; Shih C; Li T; Anderson BD; Brooks HB; Campbell RM; Considine E; Dempsey JA; Faul MM; Ogg C; Patel B; Schultz RM; Spencer CD; Teicher B; Watkins SA
    J Med Chem; 2003 May; 46(11):2027-30. PubMed ID: 12747775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
    Li X; Hou J; Li X; Jiang Y; Liu X; Mu W; Jin Y; Zhang Y; Xu W
    Eur J Med Chem; 2015 Jan; 89():628-37. PubMed ID: 25462271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis.
    Bramson HN; Corona J; Davis ST; Dickerson SH; Edelstein M; Frye SV; Gampe RT; Harris PA; Hassell A; Holmes WD; Hunter RN; Lackey KE; Lovejoy B; Luzzio MJ; Montana V; Rocque WJ; Rusnak D; Shewchuk L; Veal JM; Walker DH; Kuyper LF
    J Med Chem; 2001 Dec; 44(25):4339-58. PubMed ID: 11728181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of N9-cis-cyclobutylpurine derivatives for use as cyclin-dependent kinase (CDK) inhibitors.
    Park SJ; Kim E; Yoo M; Lee JY; Park CH; Hwang JY; Ha JD
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4399-4404. PubMed ID: 28827110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors.
    Baltus CB; Jorda R; Marot C; Berka K; Bazgier V; Kryštof V; Prié G; Viaud-Massuard MC
    Eur J Med Chem; 2016 Jan; 108():701-719. PubMed ID: 26741853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3β (GSK-3β) phosphorylation inhibitors.
    Zhao P; Li Y; Gao G; Wang S; Yan Y; Zhan X; Liu Z; Mao Z; Chen S; Wang L
    Eur J Med Chem; 2014 Oct; 86():165-74. PubMed ID: 25151579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of potent histone deacetylase inhibitors with modified phenanthridine caps.
    Fan W; Zhang L; Wang X; Jia H; Zhang L
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):707-718. PubMed ID: 33663315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
    Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
    Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.